

6 May 2026

## Botanix announces change of address

**Philadelphia PA and Phoenix AZ, 6 May 2026:** Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces that its registered office, principal place of business and postal address will change with immediate effect to:

Botanix Pharmaceuticals Limited  
Level 23, Tower 5, Collins Square  
727 Collins Street  
Melbourne, VIC 3008

All other details remain unchanged.

Release authorised by

**Vince Ippolito**  
Executive Chairman

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

General enquiries  
Corporate Communications  
Botanix Pharmaceuticals  
P: +61 8 6285 0083  
[info@botanixpharma.com](mailto:info@botanixpharma.com)

Investor enquiries  
Hannah Howlett  
P: +61 4 5064 8064  
[investors@botanixpharma.com](mailto:investors@botanixpharma.com)

Media enquiries  
Haley Chartres  
H^CK  
P: +61 423 139 163  
[haley@hck.digital](mailto:haley@hck.digital)

For personal use only